22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

IdeS: Ph II discontinued

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit profile. The company said that while...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

IdeS: Phase II started

Hansa began an open-label, U.K. Phase II trial to evaluate single doses of 0.25 and 0.5 mg/kg IV IdeS in up to 6 patients with acquired TTP and low ADAMTS13 activity who are asymptomatic. Hansa...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13)

Hematology INDICATION: Thrombocytopenia In vitro studies suggest a modified form of ADAMTS13 could help treat thrombotic thrombocytopenic purpura ( TTP ). Autoantibodies from TTP patients inhibit ADAMTS13-mediated cleavage of von Willebrand factor (vWF) by an...
07:00 , Jul 13, 2015 |  BioCentury  |  Strategy

Baxalta's blueprint

Now that Baxalta Inc. has completed its spinout from Baxter International Inc. , the newco's ambitious plan is to launch 20 new drugs, including line extensions, by 2020. The products, which come from a mix...
08:00 , Feb 24, 2011 |  BC Innovations  |  Targets & Mechanisms

A NAC for TTP

U.S. and Canadian researchers have found that the generic drug N -acetylcysteine could be repurposed for use in thrombotic thrombocytopenic purpura, a rare hematological disorder for which cumbersome plasma exchange therapy has been the standard...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Cardiovascular disease Ischemia; reperfusion injury ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13); von Willebrand factor (vWF) Studies in mice suggest that ADAMTS13 could help...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

ADAMTS13 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for ADAMTS13 to treat thrombotic thrombocytopenic purpura ( TTP ). Baxter licensed ex-Japanese rights to the disintegrin and metalloprotease...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Baxter, Chemo-Sero-Therapeutic Research Institute deal

The institute granted BAX an exclusive license to develop and commercialize recombinant ADAMTS13 worldwide, except in Japan, where the partners will co-commercialize the compound. The disintegrin and metalloprotease protein is in preclinical testing to treat...